Gilead Sciences agreed to temporarily waive certain rights under its 10-year agreement with Galapagos, allowing Galapagos to pursue external partnership opportunities for GLPG3667. Write to Katherine ...

On December 18, 2025, Galapagos reported topline data from two Phase 3-enabling trials of its selective TYK2 inhibitor GLPG3667, showing that the GALARISSO dermatomyositis study met its primary ...

GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to ...

A new study finds that experiences of discrimination are associated with worse patient-reported lupus-related symptoms and ...

Qihan Biotech, a clinical-stage biotechnology company developing off-the-shelf cell therapies for autoimmune diseases and ...

The 15-44 age range of women faces elevated danger from this condition, which shows hereditary patterns because of both ...

FDA approves AstraZeneca and Daiichi's Enhertu combo for first-line HER2-positive breast cancer, while the EU clears Saphnelo ...

(Alliance News) - AstraZeneca PLC on Tuesday said its drug Saphnelo, or anifrolumab, has been approved in the European Union as a new pre-filled pen for systemic lupus erythematosus. The Cambridge, ...

Critically ill patients with systemic lupus erythematosus show reduced ICU survival, driven largely by renal dysfunction, ...

Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE -- Zenas acquired the ...

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment in the phase IIb study. A total of 187 patients were ...